Intelgenx Technologs (IGXT) 0.5468 $IGXT
IntelGenx to Initiate Phase 1 Trial of Montelukast
Marketwire Canada - Wed Jul 13, 7:31AM CDT
SAINT-LAURENT, CANADA--(Marketwired - Jul 13, 2016) - IntelGenx Corp., (TSX VENTURE:IGX)(OTCQX:IGXT), today announced the recent initiation of a phase 1 clinical trial of montelukast, a unique drug repurposing opportunity for the treatment of degenerative diseases of the brain, such as: mild cognitive impairment and Alzheimers disease, the most prominent form of dementia. The objectives of the trial are to demonstrate: 1. IntelGenx oral film product will provide therapeutically effective blood levels of montelukast, and; 2. montelukast when delivered using IntelGenx oral film crosses the blood brain barrier.
IGX.VN: 0.710 (+0.020)
IntelGenx Announces Notice of Appeal for Buprenorphine/Naloxone Sublingual Film Product for the Treatment of Opiate Addiction
Marketwire Canada - Mon Jul 11, 3:00PM CDT
SAINT-LAURENT, QUEBEC--(Marketwired - Jul 11, 2016) - IntelGenx Corp. (TSX VENTURE:IGX)(OTCQX:IGXT), today announced the receipt of the recent notice of appeal for the buprenorphine/naloxone sublingual film product for the treatment of opiate addiction by Par Pharmaceutical, Inc. and IntelGenx Corp. to the United States Court of Appeals for the Federal Circuit from the final judgment issued by the U.S. District Court for the District of Delaware on June 28, 2016.
IGX.VN: 0.710 (+0.020)
IntelGenx Reports Amendment of Stock Option Plan
Marketwire Canada - Thu May 12, 3:01PM CDT
SAINT LAURENT, QUEBEC--(Marketwired - May 12, 2016) - IntelGenx Technologies Corp. (TSX VENTURE:IGX)(OTCQX:IGXT) (the "Company" or "IntelGenx"
reported today, that the Company's Board of Directors approved to amend the 2006 Stock Option Plan and to redesignate it as the "2016 Stock Option Plan". The number of shares available for issuance under the new Plan increased by 1,331,233 from 5,030,292 to 6,361,525, or 10% of the Company's issued and outstanding shares as of May 10, 2016. The 2016 Stock Option Plan is available on EDGAR and SEDAR for a complete review of the amendments.
IGX.VN: 0.710 (+0.020)
IntelGenx Reports First Quarter 2016 Financial Results
Marketwire Canada - Tue May 10, 3:01PM CDT
SAINT LAURENT, QUEBEC--(Marketwired - May 10, 2016) - IntelGenx Corp. (TSX VENTURE:IGX)(OTCQX:IGXT) (the "Company" or "IntelGenx" today reported its first quarter 2016 financial results for the three-month period ended March 31, 2016. All amounts are in U.S. Dollars unless otherwise stated. The Company will host a conference call to provide a corporate update on Thursday, May 12th at 9:00 a.m. ET. Details of the conference call and webcast are listed below in this release.
IGX.VN: 0.710 (+0.020)
IntelGenx to Report First Quarter 2016 Financial Results on May 10, 2016
Marketwired - Thu May 05, 5:01PM CDT
SAINT LAURENT, QUEBEC--(Marketwired - May 5, 2016) - IntelGenx Technologies Corp. (TSX VENTURE:IGX)(OTCQX:IGXT) ("IntelGenx", today announced that it will release its first quarter 2016 financial results on May 10, 2016 at 4:00 p.m. ET followed by the annual general meeting of shareholders. A special presentation will then be made by Dr. Ludwig Aigner on "Rejuvenation of the aged brain - an example of drug delivery in drug repurposing." Shareholders are then invited to the company's grand opening of its brand new state-of-the-art manufacturing facilities where tours will be offered.
IGX.VN: 0.710 (+0.020)
IntelGenx and RedHill Biopharma Announce RIZAPORT(TM) Commercialization Term Sheet With Grupo Juste for Spain and Additional Potential Territories
Marketwired - Tue Mar 29, 6:01AM CDT
IntelGenx Corp. (TSX VENTURE: IGX)(OTCQX: IGXT) and RedHill Biopharma Ltd. (NASDAQ: RDHL)(TASE: RDHL) today announced the binding term sheet agreement with Grupo Juste S.A.Q.F for the commercialization of RIZAPORT(TM), a unique oral thin film for the treatment of acute migraines in the country of Spain. The definitive agreement plans to be signed within 60 days of the execution of the binding term sheet. Financial terms of the agreement were not disclosed.
RDHL: 12.46 (+0.16), IGX.VN: 0.710 (+0.020)
RedHill Biopharma and IntelGenx Announce RIZAPORT(TM) Commercialization Term Sheet with Grupo JUSTE for Spain and Additional Potential Territories
GlobeNewswire - Tue Mar 29, 6:00AM CDT
-- RedHill and its co-development partner, IntelGenx Corp., have entered into a binding term sheet with Grupo JUSTE granting an exclusive license to commercialize their acute migraine drug RIZAPORTin Spain, and a right of first refusal for additional territories
RDHL: 12.46 (+0.16), IGX.VN: 0.710 (+0.020)
IntelGenx Announces Development and Commercialization Term Sheet with a Global Pharmaceutical Company for Up to Three Products
Marketwired - Thu Mar 24, 11:05AM CDT
IntelGenx Corp., (TSX VENTURE: IGX)(OTCQX: IGXT), today announced the signing of a term sheet with a global pharmaceutical company for the development and commercialization of up to three products utilizing IntelGenx' proprietary VersaFilm(TM) technology. Pursuant to the term sheet, IntelGenx granted an exclusive negotiation period during which time the parties will conduct diligence and work towards entry into a definitive agreement. IntelGenx receives $100,000 at the time of signing the term sheet, in consideration for granting an exclusive negotiation right. If entered into, IntelGenx expects the definitive agreement to be finalized by the second quarter of 2016.
IGX.VN: 0.710 (+0.020)
IntelGenx to Host Conference Call and Webcast of Fourth Quarter and Full-Year 2015 Financial Results on Wednesday, March 23
Marketwired - Wed Mar 09, 7:31AM CST
IntelGenx Technologies Corp. (TSX VENTURE: IGX)(OTCQX: IGXT) ("IntelGenx", today announced that it will release its fourth quarter and full-year 2015 financial results on March 22, 2016 at the close of the financial markets.
IGX.VN: 0.710 (+0.020)
IntelGenx Files Loxapine Oral Film Patent for Schizophrenia
Marketwired - Wed Feb 10, 7:31AM CST
IntelGenx Corp., (TSX VENTURE: IGX)(OTCQX: IGXT), today announced that it has submitted a patent application with the US patent office for an oral film dosage form containing Loxapine for the treatment of anxiety and aggression in patients suffering from schizophrenia or bipolar 1 disorder.
IGX.VN: 0.710 (+0.020)
IntelGenx Announces Creation of a Scientific Advisory Board
Marketwired - Thu Feb 04, 7:31AM CST
IntelGenx Corp., (TSX VENTURE: IGX)(OTCQX: IGXT), today announced that it has further strengthened its organization with the creation of a Scientific Advisory Board with the engagement of Dr. Ludwig Aigner and Dr. Barry Greenberg. Dr. Horst G. Zerbe will act as the Chairman and Ms. Nadine Paiement (Vice President, Research and Development) will serve as Vice-Chair of the Scientific Advisory Board.
IGX.VN: 0.710 (+0.020)
IntelGenx to Initiate Phase 1 Trial of Montelukast
Marketwire Canada - Wed Jul 13, 7:31AM CDT
SAINT-LAURENT, CANADA--(Marketwired - Jul 13, 2016) - IntelGenx Corp., (TSX VENTURE:IGX)(OTCQX:IGXT), today announced the recent initiation of a phase 1 clinical trial of montelukast, a unique drug repurposing opportunity for the treatment of degenerative diseases of the brain, such as: mild cognitive impairment and Alzheimers disease, the most prominent form of dementia. The objectives of the trial are to demonstrate: 1. IntelGenx oral film product will provide therapeutically effective blood levels of montelukast, and; 2. montelukast when delivered using IntelGenx oral film crosses the blood brain barrier.
IGX.VN: 0.710 (+0.020)
IntelGenx Announces Notice of Appeal for Buprenorphine/Naloxone Sublingual Film Product for the Treatment of Opiate Addiction
Marketwire Canada - Mon Jul 11, 3:00PM CDT
SAINT-LAURENT, QUEBEC--(Marketwired - Jul 11, 2016) - IntelGenx Corp. (TSX VENTURE:IGX)(OTCQX:IGXT), today announced the receipt of the recent notice of appeal for the buprenorphine/naloxone sublingual film product for the treatment of opiate addiction by Par Pharmaceutical, Inc. and IntelGenx Corp. to the United States Court of Appeals for the Federal Circuit from the final judgment issued by the U.S. District Court for the District of Delaware on June 28, 2016.
IGX.VN: 0.710 (+0.020)
IntelGenx Reports Amendment of Stock Option Plan
Marketwire Canada - Thu May 12, 3:01PM CDT
SAINT LAURENT, QUEBEC--(Marketwired - May 12, 2016) - IntelGenx Technologies Corp. (TSX VENTURE:IGX)(OTCQX:IGXT) (the "Company" or "IntelGenx"
reported today, that the Company's Board of Directors approved to amend the 2006 Stock Option Plan and to redesignate it as the "2016 Stock Option Plan". The number of shares available for issuance under the new Plan increased by 1,331,233 from 5,030,292 to 6,361,525, or 10% of the Company's issued and outstanding shares as of May 10, 2016. The 2016 Stock Option Plan is available on EDGAR and SEDAR for a complete review of the amendments. IGX.VN: 0.710 (+0.020)
IntelGenx Reports First Quarter 2016 Financial Results
Marketwire Canada - Tue May 10, 3:01PM CDT
SAINT LAURENT, QUEBEC--(Marketwired - May 10, 2016) - IntelGenx Corp. (TSX VENTURE:IGX)(OTCQX:IGXT) (the "Company" or "IntelGenx"
today reported its first quarter 2016 financial results for the three-month period ended March 31, 2016. All amounts are in U.S. Dollars unless otherwise stated. The Company will host a conference call to provide a corporate update on Thursday, May 12th at 9:00 a.m. ET. Details of the conference call and webcast are listed below in this release. IGX.VN: 0.710 (+0.020)
IntelGenx to Report First Quarter 2016 Financial Results on May 10, 2016
Marketwired - Thu May 05, 5:01PM CDT
SAINT LAURENT, QUEBEC--(Marketwired - May 5, 2016) - IntelGenx Technologies Corp. (TSX VENTURE:IGX)(OTCQX:IGXT) ("IntelGenx"
, today announced that it will release its first quarter 2016 financial results on May 10, 2016 at 4:00 p.m. ET followed by the annual general meeting of shareholders. A special presentation will then be made by Dr. Ludwig Aigner on "Rejuvenation of the aged brain - an example of drug delivery in drug repurposing." Shareholders are then invited to the company's grand opening of its brand new state-of-the-art manufacturing facilities where tours will be offered. IGX.VN: 0.710 (+0.020)
IntelGenx and RedHill Biopharma Announce RIZAPORT(TM) Commercialization Term Sheet With Grupo Juste for Spain and Additional Potential Territories
Marketwired - Tue Mar 29, 6:01AM CDT
IntelGenx Corp. (TSX VENTURE: IGX)(OTCQX: IGXT) and RedHill Biopharma Ltd. (NASDAQ: RDHL)(TASE: RDHL) today announced the binding term sheet agreement with Grupo Juste S.A.Q.F for the commercialization of RIZAPORT(TM), a unique oral thin film for the treatment of acute migraines in the country of Spain. The definitive agreement plans to be signed within 60 days of the execution of the binding term sheet. Financial terms of the agreement were not disclosed.
RDHL: 12.46 (+0.16), IGX.VN: 0.710 (+0.020)
RedHill Biopharma and IntelGenx Announce RIZAPORT(TM) Commercialization Term Sheet with Grupo JUSTE for Spain and Additional Potential Territories
GlobeNewswire - Tue Mar 29, 6:00AM CDT
-- RedHill and its co-development partner, IntelGenx Corp., have entered into a binding term sheet with Grupo JUSTE granting an exclusive license to commercialize their acute migraine drug RIZAPORTin Spain, and a right of first refusal for additional territories
RDHL: 12.46 (+0.16), IGX.VN: 0.710 (+0.020)
IntelGenx Announces Development and Commercialization Term Sheet with a Global Pharmaceutical Company for Up to Three Products
Marketwired - Thu Mar 24, 11:05AM CDT
IntelGenx Corp., (TSX VENTURE: IGX)(OTCQX: IGXT), today announced the signing of a term sheet with a global pharmaceutical company for the development and commercialization of up to three products utilizing IntelGenx' proprietary VersaFilm(TM) technology. Pursuant to the term sheet, IntelGenx granted an exclusive negotiation period during which time the parties will conduct diligence and work towards entry into a definitive agreement. IntelGenx receives $100,000 at the time of signing the term sheet, in consideration for granting an exclusive negotiation right. If entered into, IntelGenx expects the definitive agreement to be finalized by the second quarter of 2016.
IGX.VN: 0.710 (+0.020)
IntelGenx to Host Conference Call and Webcast of Fourth Quarter and Full-Year 2015 Financial Results on Wednesday, March 23
Marketwired - Wed Mar 09, 7:31AM CST
IntelGenx Technologies Corp. (TSX VENTURE: IGX)(OTCQX: IGXT) ("IntelGenx"
, today announced that it will release its fourth quarter and full-year 2015 financial results on March 22, 2016 at the close of the financial markets. IGX.VN: 0.710 (+0.020)
IntelGenx Files Loxapine Oral Film Patent for Schizophrenia
Marketwired - Wed Feb 10, 7:31AM CST
IntelGenx Corp., (TSX VENTURE: IGX)(OTCQX: IGXT), today announced that it has submitted a patent application with the US patent office for an oral film dosage form containing Loxapine for the treatment of anxiety and aggression in patients suffering from schizophrenia or bipolar 1 disorder.
IGX.VN: 0.710 (+0.020)
IntelGenx Announces Creation of a Scientific Advisory Board
Marketwired - Thu Feb 04, 7:31AM CST
IntelGenx Corp., (TSX VENTURE: IGX)(OTCQX: IGXT), today announced that it has further strengthened its organization with the creation of a Scientific Advisory Board with the engagement of Dr. Ludwig Aigner and Dr. Barry Greenberg. Dr. Horst G. Zerbe will act as the Chairman and Ms. Nadine Paiement (Vice President, Research and Development) will serve as Vice-Chair of the Scientific Advisory Board.
IGX.VN: 0.710 (+0.020)
